A reduced dosing strategy can work for Alectinib in ALK rearranged non small cell lung cancer

被引：0
|
作者：
Sacdalan, Danielle Benedict [1 ,2 ]
Lucero, Josephine Anne [2 ]
机构：
[1] Univ Toronto, Inst Med Sci, Temerty Fac Med, Toronto, ON, Canada
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
CANCER TREATMENT AND RESEARCH COMMUNICATIONS | 2022年 / 33卷
关键词：
D O I：
10.1016/j.ctarc.2022.100662
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Alectinib in resected ALK-positive non-small-cell lung cancer
    Gourmet, Anais
    Ferrari, Victoria
    BULLETIN DU CANCER, 2024, 111 (10) : 905 - 906
  • [22] Alectinib for advanced ALK-positive non-small-cell lung cancer
    Ly, Ashley C.
    Olin, Jacqueline L.
    Smith, Morgan B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (08) : 515 - 522
  • [23] Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Dziadziuszko, Rafal
    Ahn, Jin Seok
    Barlesi, Fabrice
    Nishio, Makoto
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Mao, Weimin
    Hochmair, Maximilian
    de Marinis, Filippo
    Migliorino, M. Rita
    Bondarenko, Igor
    Lu, Shun
    Wang, Qun
    Ochi Lohmann, Tania
    Xu, Tingting
    Cardona, Andres
    Ruf, Thorsten
    Noe, Johannes
    Solomon, Benjamin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1265 - 1276
  • [24] Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer
    Shiihara, Jun
    Ohyanagi, Fumiyoshi
    Amari, Hikari
    Toda, Minemichi
    Tahara, Hiroki
    Yuzawa, Motoi
    Maeda, Yuki
    Nomura, Motoko
    Mizushina, Yoshiko
    Nagai, Yoshiaki
    Ohta, Hiromitsu
    Yamaguchi, Yasuhiro
    THORACIC CANCER, 2021, 12 (17) : 2420 - 2423
  • [25] Alectinib for treatment of ALK-positive non-small-cell lung cancer
    Avrillon, Virginie
    Perol, Maurice
    FUTURE ONCOLOGY, 2017, 13 (04) : 321 - 335
  • [26] Crizotinib could overcome acquired resistance to alectinib caused by HGF autocrine in ALK rearranged non-small cell lung cancer abstracts
    Isozaki, H.
    Ichihara, E.
    Takigawa, N.
    Ohashi, K.
    Ochi, N.
    Yasugi, M.
    Ninomiya, T.
    Yamane, H.
    Minami, D.
    Kubo, T.
    Sato, A.
    Hotta, K.
    Sakai, K.
    Matsumoto, K.
    Hosokawa, S.
    Bessho, A.
    Sendo, T.
    Tanimoto, M.
    Kiura, K.
    ANNALS OF ONCOLOGY, 2015, 26 : 1 - 1
  • [27] FISH and IHC Discordance in ALK Rearranged Non-Small Cell Lung Cancer
    Kapoor, A.
    Noronha, V.
    Joshi, A.
    Patil, V.
    Kaushal, R.
    Mahajan, A.
    Janu, A.
    Prabhash, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1900 - S1900
  • [28] Targeting ALK-rearranged non-small-cell lung cancer: an update
    Sullivan, Ivana
    Planchard, David
    FUTURE ONCOLOGY, 2017, 13 (14) : 1213 - 1217
  • [29] Activating alternative receptor tyrosine kinases induced alectinib-resistance in ALK rearranged non-small cell lung cancer cells
    Isozaki, Hideko
    Ichihara, Eiki
    Yasugi, Masayuki
    Takigawa, Nagio
    Ohashi, Kadoaki
    Kubo, Toshio
    Ninomiya, Takashi
    Ochi, Nobuaki
    Minami, Daisuke
    Kudo, Kenichiro
    Kato, Yuka
    Kayatani, Hiroe
    Tamura, Tomoki
    Ninonniya, Kiichiro
    Higo, Toshio
    Makimoto, Tsuyoshi
    Sato, Akiko
    Hotta, Katsuyuki
    Matsumoto, Kunio
    Sendo, Toshiaki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CANCER RESEARCH, 2016, 76
  • [30] Sequential Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study
    Ito, Kentaro
    Hataji, Osamu
    Kobayashi, Hiroyasu
    Fujiwara, Atsushi
    Yoshida, Masamichi
    D'Alessandro-Gabazza, Corina N.
    Itani, Hidetoshi
    Tanigawa, Motoaki
    Ikeda, Takuya
    Fujiwara, Kentaro
    Fujimoto, Hajime
    Kobayashi, Tetsu
    Gabazza, Esteban C.
    Taguchi, Osamu
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) : 390 - 396
12345